Dietmar Berger, Chief Medical Officer at Gilead Sciences, shared a post on LinkedIn:
“The energy at ASCO26 reflects just how fast oncology is moving—and how much more is now within reach.
Kicking off the week at STAT ASCO, what stood out wasn’t just the volume of data, but the direction of the field.
At Gilead Sciences and Kite Pharma, that shift is visible every day. From advances in ADC science to the continued momentum in CAR T, the work isn’t simply tracking where oncology is headed—it’s helping shape what comes next.
In conversation with Rick Berke of STAT, the focus was on what lies ahead: reaching patients earlier, designing therapies with greater precision, and pushing cell therapy beyond its current boundaries.
The future isn’t about a single modality. It’s about convergence—killing cancer cells, engaging the immune system, and removing the conditions that allow cancer to thrive.
The pace of progress is real. And with it comes a meaningful opportunity to change outcomes for patients.
Looking forward to the conversations ahead.”
Other articles about Gilead Sciences on Oncodaily.